The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Open accessAbstract
The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (FEV 1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort®) 160/4.5 µg (delivered dose), budesonide 200 µg (metered dose), formoterol 4.5 µg or placebo. Severe exacerbations and FEV 1(primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever β 2‐agonist and safety variables were recorded. Budesonide/formoterol reduced the mean number of severe exacerbations per patient per year by 24%versus placebo and 23%versus formoterol. FEV 1 increased by 15%versus placebo and 9%versus budesonide. Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol. Improvements in morning and evening PEF versus comparators were maintained over 12 months. Budesonide/formoterol decreased all symptom scores and use of reliever β 2‐agonists significantly versus placebo and budesonide, and improved HRQL versus placebo. All treatments were well tolerated. These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
Pauwels, R. A., Löfdahl, C.-G., Postma, D. S., Tattersfield, A. E., O'Byrne, P., Barnes, P. J., & Ullman, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711133372001 · Cited by 1,520
Anthonisen, N. R. (1994) · JAMA · doi:10.1001/jama.1994.03520190043033 · Cited by 1,341
Pauwels, R. A., Löfdahl, C.-G., Laitinen, L. A., Schouten, J. P., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402503 · Cited by 1,074
SEEMUNGAL, T., HARPER-OWEN, R., BHOWMIK, A., MORIC, I., SANDERSON, G., MESSAGE, S., MacCALLUM, P., MEADE, T. W., JEFFRIES, D. J., JOHNSTON, S. L., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2105011 · Cited by 1,018
Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
(1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380222 · Cited by 864
(2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432601 · Cited by 830
SCANLON, P. D., CONNETT, J. E., WALLER, L. A., ALTOSE, M. D., BAILEY, W. C., SONIA BUIST, A., & e Lung Health Study Research Group, D. P. T. F. T. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9901044 · Cited by 731
Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma: The OPTIMA Randomized Trial
O'BYRNE, P. M., BARNES, P. J., RODRIGUEZ-ROISIN, R., RUNNERSTROM, E., SANDSTROM, T., SVENSSON, K., & TATTERSFIELD, A. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.8.2104102 · Cited by 680
Paggiaro, P. L., Dahle, R., Bakran, I., Frith, L., Hollingworth, K., & Efthimiou, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)03471-5 · Cited by 508
Quality of life changes in COPD patients treated with salmeterol.
Jones, P. W., & Bosh, T. K. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.4.9105068 · Cited by 494
Buist, A. S., & Connett, J. E. (1993) · Chest · doi:10.1378/chest.103.6.1644a · Cited by 483
Ongoing airway inflammation in patients with COPD who do not currently smoke
Rutgers, S. R. (2000) · Thorax · doi:10.1136/thorax.55.1.12 · Cited by 398
SIN, D. D., & TU, J. V. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.4.2009033 · Cited by 305
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
Boyd, G., Morice, A., Pounsford, J., Siebert, M., Peslis, N., & Crawford, C. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10040815 · Cited by 269
Effect of smoking cessation on airway inflammation in chronic bronchitis.
Turato, G., Di Stefano, A., Maestrelli, P., Mapp, C. E., Ruggieri, M. P., Roggeri, A., Fabbri, L. M., & Saetta, M. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.4.7551380 · Cited by 210
Jarad, N. A., Wedzicha, J. A., Burge, P. S., & Calverley, P. M. A. (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90001-x · Cited by 160
Aalbers, R., Ayres, J. G., Backer, V., Decramer, M., Lier, P. A., Magyar, P., Małolepszy, J., Ruffin, R. E., & Sybrecht, G. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00240902 · Cited by 153
Cazzola, M., Matera, M. G., Santangelo, G., Vinciguerra, A., Rossi, F., & D’Amato, G. (1995) · Respiratory Medicine · doi:10.1016/0954-6111(95)90008-x · Cited by 151
Johnell, O., Pauwels, R., Lofdahl, C., Laitinen, L. A., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00276602 · Cited by 112
Spirometry and Dyspnea in Patients With COPD
Redelmeier, D. A., Goldstein, R. S., Min, S. T., & Hyland, R. H. (1996) · CHEST Journal · doi:10.1378/chest.109.5.1163 · Cited by 110
Korn, S. H., Jerre, A., & Brattsand, R. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00073301 · Cited by 110
Long-Acting ??2 Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease
Cazzola, M., & Donner, C. F. (2000) · Drugs · doi:10.2165/00003495-200060020-00005 · Cited by 73
Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease
Scanlon, P. D., Connett, J. E., Waller, L. A., Altose, M. D., Bailey, W. C., Buist, A. S., & Tashkin, D. P. (2000) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200007000-00015 · Cited by 65
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts
SPOELSTRA, F. M., Postma, D. S., Hovenga, H., Noordhoek, J. A., & Kauffman, H. F. (2002) · Thorax · doi:10.1136/thorax.57.3.237 · Cited by 64
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
“An inhaled glucocorticosteroid combined with a long-acting b2-agonist is more effective than the individual components (123, 125, 126, 130, 131) (Evidence A).”
BackgroundCelli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Metadata
- Authors
- Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2003-01
- Volume
- 21
- Issue
- 1
- Pages
- 74-81
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2145152803
- Cited by
- 887
- References
- 28
- FWCI
- 66.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.